Phio Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that CEO Robert Bitterman will present an overview of its INTASYL siRNA gene silencing technology and its lead clinical candidate PH-762, aimed at treating skin cancers like cutaneous carcinomas. The presentation will take place on July 28, 2026, at 12 PM EDT during a virtual non-deal roadshow hosted by Renmark Financial. PH-762 is designed to silence the PD-1 gene to enhance immune response against cancer cells and is currently in Phase 1b trials. This event offers investors insight into Phio's innovative approach to immuno-oncology and the potential of its technology to advance cancer treatments.
Ipsen Pharma issued a correction to its monthly report on the total number of shares and voting rights as of June 30, 2026. The correction addresses a material error in the previously published figures for both gross and net voting rights. The update...
Ipsen Pharma issued a corrective statement to amend its previously published monthly disclosure of the total number of shares and voting rights as of June 30, 2026. The correction addresses a material error in the reported gross and net voting rights...
Alstom announced a 4.9% increase in revenue to €4.734 billion for Q1 of fiscal year 2026/27, driven by strong performance in rolling stock, services, and signaling. Despite a 37% drop in new orders to €2.56 billion, the company achieved major operati...
Alstom posted a 4.9% increase in sales to €4.73 billion for Q1 FY 2026/27, driven by progress in rolling stock, services, and signalling. Despite a 37% drop in orders to €2.56 billion, the company achieved major milestones including TGV-M homologatio...
Teledyne Technologies reported strong Q2 2026 results, with earnings per share of $6.28 beating estimates by 8.65% and revenue of $1.66 billion surpassing expectations. The company saw a 20.8% increase in EPS and a 9.8% rise in revenue year-over-year...
